VHH EE
An anti-RBD (SARS-CoV-2 Spike) bivalent fusion nanobody.
General information
VHH EE is a bivalent fusion nanobody derived from VHH E, which is specific for SARS-CoV-2 Spike RBD. The parent monovalent nanobody was identified using the phage display technique and originally produced by an immune cell of a llama immunized with SARS-CoV-2 Spike RBD and inactivated SARS-CoV-2 virus. VHH EE is more potent in virus neutralization than VHH E. The bivalent nanobody likely inhibits RBD binding to ACE2 (Koenig et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Spike protein ACE2 Cryo-EM Crystallization Biophysical assay In vitro Mechanism Antibody |
llama and alpaca immune cells (source); in vitro biophysical assay; cryo-EM; crystallization; Vero E6 cells; Caco-2 cells; HEK293T cells; hACE2-HEK293T cells; SARS-CoV-2 Spike Δ18 pseudovirus; SARS-CoV-2 isolate SARS-CoV-2/human/Germany/Heinsberg-01/2020 | 41.85 | In vitro, the bivalent nanobody inhibited SARS-CoV-2 Spike pseudotyped virus and live virus infection with IC50s of 0.93 nM and 0.18 nM, respectively. |
Feb/12/2021 |
